Sonodynamic therapy (SDT) is a novel tumor treatment that combines biosafe sonosensitizers and noninvasive focused ultrasound to eradicate solid tumors. Sonosensitizers such as 5-aminolevulinic acid and fluorescein have great potential in tumor treatment. Here, rodent subcutaneous and brain tumor models were used to evaluate the treatment effect of both 5-ALA- and fluorescein-mediated SDT. The subcutaneous tumor growth rates of both SDT groups were significantly inhibited compared with that of the control groups. For intracranial tumors, 5-ALA-SDT treatment significantly inhibited brain tumor growth, while fluorescein-SDT exerted no therapeutic effect in animals. The distribution of fluorescein in the brain tumor region underwent further assessment. Seven days post tumor implantation, experimental animals received fluorescein and were sacrificed for brain specimen collection. Analysis of the dissected brains revealed no fluorescence signals, indicating an absence of fluorescein accumulation in the early-stage glioma tissue. These data suggest that the fluorescein-SDT treatment response is closely related to the amount of accumulated fluorescein. This study reports the equivalent effects of 5-ALA and fluorescein on the treatment of somatic tumors. For orthotopic brain tumor models, tumor vascular permeability should be considered when choosing fluorescein as a sonosensitizer. In conclusion, both fluorescein and 5-ALA are safe and effective SDT sonosensitizers, and the tumor microenvironment and pathologic type should be considered in the selection of adequate sonosensitizers.
声动力疗法是一种结合生物安全性声敏剂与无创聚焦超声以根除实体肿瘤的新型肿瘤治疗方法。5-氨基乙酰丙酸和荧光素等声敏剂在肿瘤治疗中具有巨大潜力。本研究采用啮齿动物皮下及脑肿瘤模型，评估了5-ALA与荧光素介导的声动力治疗效果。与对照组相比，两种声动力治疗组的皮下肿瘤生长速率均受到显著抑制。对于颅内肿瘤，5-ALA声动力治疗显著抑制了脑肿瘤生长，而荧光素声动力治疗在动物模型中未产生治疗效果。进一步评估了荧光素在脑肿瘤区域的分布情况：肿瘤植入七天后，实验动物接受荧光素注射并采集脑组织标本，解剖分析显示脑组织无荧光信号，表明早期胶质瘤组织中不存在荧光素蓄积。这些数据表明荧光素声动力治疗效果与荧光素蓄积量密切相关。本研究报道了5-ALA与荧光素在体表肿瘤治疗中的等效作用，针对原位脑肿瘤模型，选择荧光素作为声敏剂时应考虑肿瘤血管通透性因素。综上所述，荧光素与5-ALA均为安全有效的声动力声敏剂，在选择适宜声敏剂时应综合考虑肿瘤微环境及病理类型。
肿瘤(癌症)患者之家